Regular ArticleEndothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism
Introduction
Microparticles (MPs) are phospholipid vesicles, smaller than 1 μm in diameter, derived mainly from blood and endothelial cells, in response to activation or apoptosis. MPs release is an integral part of the membrane-remodelling process in which the asymmetric distribution of constitutive phospholipids between the two leaflets is lost [1]. MPs are detected and characterized on the basis of antigens characteristic of their respective parental cells [2]. Found at the electronic microscopy since 1967 by Wolf and coll. [3], MPs were considered “cellular dust” without any biological function. Recently it has been hypothesized that MPs play a role in inflammation, coagulation and vascular function [4], and it was demonstrated that these elements could induce cell signalling [5] and regulate many pathophysiological processes [6] including neoangiogenesis [7]. Moreover, a procoagulant function has been attributed to MPs, due to the presence phospholipids on their outer surface, in particular phosphatidilserine (PS), which could induce the activation of the coagulation cascade. This procoagulant role is amplified by the capability of PS to activate tissue factor (TF) [8]. Elevated MPs of different phenotypes have been documented in the blood of patients with venous thromboembolism (VTE) [9], [10], [11] and with various diseases characterized by arterial and venous thrombotic complications (i.e. heparin induced thrombocytopenia [12], cardiovascular diseases [13], [14], thrombotic thrombocytopenic purpura [15], sickle cells diseases [16], uraemia [17], diabetes [18] and anti-phospholipid antibody syndrome [19]). Thromboembolic disease is a well recognized complication of cancer. Clinical studies reported that approximately 5–15% of all cancer patients develop thrombotic events [20], [21]. However, despite this strong association between VTE and malignant diseases, the molecular and cellular bases of this relationship remain uncertain. Recent studies have shown that cancer patients with VTE have higher MPs levels than cancer patients without thrombosis [22], [23], [24], [25]. In this case-control study we evaluated the role of endothelial (E-), platelet (P-) and TF+MPs in the development of cancer-associated thrombosis.
Section snippets
Material and Methods
Out of 145 patients consecutively admitted from January 2007 to June 2008 to the Thrombotic Unit and Oncology Department at the Padua University Hospital, 90 patients (M/F 42/48; age range 40-92 yrs) were enrolled in the study: thirty patients (M/F 12/18; age range 43-79 yrs) with a first episode of objectively confirmed acute unprovoked VTE [at diagnosis, and before anticoagulant therapy was started]; 30 (M/F 15/15; age range 45-89 yrs) with active cancer [diagnosis less than six months before
MPs in patients and controls
Enrolment of study patients is reported in Fig. 1. The total study population, consisted of 90 patients, showed higher (mean ± SD) circulating EMPs and PMPs plasma levels (920 ± 341 and 1221 ± 413 MPs/μL, respectively) than controls (299 ± 102 and 495 ± 241 MPs/μL). The difference was statistically significant (p = 0.005 and 0.001, respectively). The analysis of sex-specific differences showed a statistically significant higher PMPs level (mean ± SD) in female (1324 ± 712 MPs/μL) than in male (1089 ± 821 MPs/μL;
Discussion
In this study we investigated quantitative and “qualitative” characteristics of circulating MPs in a group of cancer patients, with and without VTE, and in a group with acute unprovoked VTE compared to a healthy control population. EMPs, PMPs, and TF+MPs plasma levels were significantly higher in both groups of patients than in healthy subjects.
The pathogenesis of VTE in cancer is multifactorial and rather unclear. Recently, increasing evidence link MPs to cancer associated thrombosis. In
Conflict of interest
None.
Acknowledgements
We thank Laura Salmaso for her kind support in statistical analysis.
References (30)
Cellular microparticles: what are they bad or good for?
J Thromb Haemost
(2003)- et al.
Microparticles during sepsis and trauma. A link between inflammation and thrombotic processes
Ann Fr Anesth Rèanim
(2006) - et al.
Measuring circulating cell-derived microparticles
J Thromb Haemost
(2004) - et al.
Elevation of endothelial microparticles, platelets, and leucocyte activation in patients with venous thromboemoblism
J Am Coll Cardiol
(2005) - et al.
Plasma levels of microparticles-associated tissue factor activity in patients with clinically suspected pulmonary embolism
Thromb Res
(2010) - et al.
Circulating procoagulant microparticles in patients with venous thromboembolism
Thromb Res
(2009) - et al.
Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients
Kidney Int
(2002) - et al.
Microparticle-associated tissue factor activity: a link between cancer and thrombosis?
J Thromb Heamost
(2007) - et al.
Microparticle-associated tissue factor activity in cancer patients with and without thrombosis
J Thromb Haemost
(2009) - et al.
Increased microparticle tissue factor activity in cancer patients with venous thromboembolism
Thromb Res
(2010)
Flow cytometric detection of endothelial microparticles (EMP): Effects of centrifugation and storage alter with the phenotype studied
Thromb Res
Cell-derived microparticles: “Miniature envoys with many faces”
J Thromb Haemost
The nature and significance of platelet products in human plasma
Br J Haematol
Microparticles in cardiovascular diseases
Cardiovasc Res
Cellular microparticles: a disseminated storage pool of bioactive vascular effectors
Curr Opin Haematology
Cited by (122)
Detection of tissue factor–positive extracellular vesicles using the ExoView R100 system
2023, Research and Practice in Thrombosis and HaemostasisSubtype-specific plasma signatures of platelet-related protein releasate in acute pulmonary embolism
2022, Thrombosis ResearchCitation Excerpt :Although we attributed distinct platelet-related proteins to the release via EV, i.e. microparticles, exosomes and apoptotic bodies [68], this study did not address the quantification and characterization of EV in the plasma of VTE phenotypes. There is accumulating evidence that cancer-associated VTE is linked to increased plasma levels of microparticles, including platelet-derived microparticles [69,70]. In non-cancer patients, a significant increase in platelet-derived microparticles was only observed with recurrent but not with initial or unprovoked VTE compared to healthy blood donors [71,72].
The Role of Biomarkers, Metabolomics, and COVID-19 in Venous Thromboembolism—A Review of Literature
2023, International Journal of Molecular Sciences